| Literature DB >> 26483044 |
Torunn Varmdal1, Hanne Ellekjær2, Hild Fjærtoft3,4, Bent Indredavik5,6, Stian Lydersen7, Kaare Harald Bonaa8,9,10.
Abstract
BACKGROUND: Medical quality registers are useful sources of knowledge about diseases and the health services. However, there are challenges in obtaining valid and reliable data. This study aims to assess the reliability in a national medical quality register.Entities:
Mesh:
Year: 2015 PMID: 26483044 PMCID: PMC4617717 DOI: 10.1186/s13104-015-1556-3
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Inter-rater reliability for medical history, functional status prior to stroke onset and pre-hospital data
| N | Obs.agr. (%)a | Kappa (95 % CI) | AC1 (95 % CI) | |
|---|---|---|---|---|
| Past medical history | ||||
| Previous stroke | 111 | 92.8 | 0.81 (0.69–0.94) | 0.91 (0.85–0.97) |
| Myocardial infarction | 111 | 96.4 | 0.87 (0.75–0.99) | 0.95 (0.90–1.00) |
| Major cardiac interventions | 111 | 92.8 | 0.66 (0.43–0.88) | 0.92 (0.86–0.98) |
| Atrial fibrillation | 111 | 89.2 | 0.71 (0.56–0.86) | 0.87 (0.79–0.94) |
| Diabetes | 109 | 97.2 | 0.92 (0.83–1.00) | 0.96 (0.91–1.00) |
| TIA (transient ischemic attack) | 111 | 91.9 | 0.54 (0.27–0.81) | 0.91 (0.85–0.97) |
| Drug treatment prior to stroke onset | ||||
| Aspirin (ASA) | 110 | 97.3 | 0.94 (0.87–1.00) | 0.95 (0.89–1.00) |
| ADP receptor antagonist | 110 | 98.2 | 0.74 (0.40–1.00) | 0.98 (0.96–1.00) |
| Dipyridamole | 110 | 95.5 | 0.60 (0.28–0.92) | 0.95 (0.91–0.99) |
| Warfarin | 111 | 98.2 | 0.93 (0.83–1.00) | 0.98 (0.95–1.00) |
| Diuretics | 111 | 86.5 | 0.60 (0.42–0.78) | 0.84 (0.76–0.92) |
| ACE-inhibitor | 110 | 98.2 | 0.91 (0.80–1.00) | 0.98 (0.95–1.00) |
| A2-receptor blocker | 110 | 92.7 | 0.70 (0.52–0.89) | 0.92 (0.86–0.98) |
| Beta blocker | 111 | 95.5 | 0.91 (0.82–0.99) | 0.94 (0.90–0.99) |
| Calcium channel blocker | 109 | 94.5 | 0.74 (0.54–0.94) | 0.94 (0.90–0.99) |
| Statins | 111 | 97.3 | 0.94 (0.87–1.00) | 0.95 (0.90–1.00) |
| Other drugs against hypertension | 111 | 72.0 | 0.48 (0.34–0.61) | 0.63 (0.51–0.74) |
| Functional status prior to stroke | ||||
| Housingb | 110 | 98.2 | 0.88 (0.80–0.96) | 0.97 (0.94–0.99) |
| Functional mobilityb | 104 | 98.1 | 0.83 (0.67–0.98) | 0.98 (0.96–0.99) |
| Marital status | 111 | 75.7 | 0.62 (0.52–0.72) | 0.69 (0.58–0.80) |
| Living situation | 106 | 91.0 | 0.84 (0.75–0.93) | 0.89 (0.82–0.96) |
| Toilet hygiene | 111 | 88.3 | 0.44 (0.24–0.65) | 0.87 (0.80–0.94) |
| Dressing | 111 | 87.4 | 0.55 (0.37–0.73) | 0.85 (0.78–0.93) |
| On stroke onset | ||||
| Patient woke with stroke symptoms? | 108 | 62.0 | 0.28 (0.11–0.44) | 0.49 (0.35–0.62) |
| Place of stroke onset | 110 | 96.4 | 0.58 (0.21–0.96) | 0.96 (0.92–1.00) |
aObserved agreement calculated as concordant answers divided by N
bOrdinal data, estimate based on Cohen’s quadratic weighted kappa and Gwet’s AC2
Inter-rater reliability for symptoms, diagnostic procedures, treatment and stroke subtype
| N | Obs.agr. (%)a | Kappa (95 % CI) | AC1 (95 % CI) | |
|---|---|---|---|---|
| Symptoms at admission | ||||
| Hemiparesis face | 108 | 79.6 | 0.64 (0.51–0.77) | 0.72 (0.61–0.83) |
| Hemiparesis legs | 110 | 73.6 | 0.54 (0.41–0.68) | 0.63 (0.51–0.75) |
| Hemiparesis arms | 109 | 80.0 | 0.62 (0.49–0.75) | 0.73 (0.62–0.83) |
| Speech problems | 107 | 72.9 | 0.52 (0.37–0.66) | 0.62 (0.50–0.75) |
| Other focal symptoms | 111 | 62.2 | 0.37 (0.22–0.53) | 0.46 (0.33–0.59) |
| Symptoms at right/left side | 111 | 79.3 | 0.69 (0.58–0.79) | 0.73 (0.64–0.84) |
| Level of consciousnessb | 109 | 95.8 | 0.66 (0.47–0.85) | 0.93 (0.89–0.98) |
| Diagnostic imaging and examinations | ||||
| CT/MRI <24 h after admission | 110 | 97.3 | 0.69 (0.39–0.99) | 0.97 (0.94–1.00) |
| Imaging of the stroke | 109 | 87.2 | 0.77 (0.66–0.87) | 0.84 (0.76–0.92) |
| Imaging of intracranial vessels | 110 | 91.0 | 0.56 (0.33–0.79) | 0.90 (0.85–0.96) |
| Imaging of extracranial vessels | 110 | 83.6 | 0.71 (0.59–0.83) | 0.82 (0.74–0.90) |
| Imaging of the heart | 111 | 89.2 | 0.68 (0.52–0.85) | 0.88 (0.82–0.95) |
| Heart rate monitoring | 111 | 52.2 | 0.17 (0.03–0.31) | 0.46 (0.35–0.57) |
| Treatment and diagnosis | ||||
| Anticoagulants as treatment | 111 | 88.3 | 0.34 (0.04–0.60) | 0.87 (0.80–0.94) |
| Anticoagulants as prophylaxis | 111 | 86.5 | 0.56 (0.36–0.76) | 0.84 (0.76–0.92) |
| Swallowing test performed | 111 | 48.6 | 0.19 (0.09–0.30) | 0.27 (0.12–0.43) |
| Mobilized out of bed <24 h | 110 | 21.8 | 0.04 (0.00–0.09) | −0.11 (0.00–0.01) |
| Stroke subtype | 111 | 99.1 | 0.97 (0.90–1.00) | 0.99 (0.97–1.00) |
aObserved agreement calculated as concordant answers divided by N
bOrdinal data, estimate based on Cohen’s quadratic weighted kappa and Gwet’s AC2
Inter-rater reliability for discharge data
| N | Obs.agr. (%)a | Kappa (95 % CI) | AC1 (95 % CI) | |
|---|---|---|---|---|
| Discharge destination | ||||
| Discharge destination | 111 | 74.8 | 0.69 (0.60–0.79) | 0.72 (0.63–0.81) |
| Drug treatment at discharge | ||||
| Aspirin (ASA) | 110 | 73.6 | 0.51 (0.38–0.64) | 0.65 (0.54–0.76) |
| ADP receptor antagonist | 110 | 99.1 | 0.94 (0.83–1.00) | 0.99 (0.97–1.00) |
| Dipyridamole | 110 | 71.0 | 0.25 (0.10–0.41) | 0.65 (0.53–0.76) |
| Warfarin | 110 | 96.4 | 0.85 (0.70–0.99) | 0.96 (0.92–0.99) |
| Diuretics | 110 | 88.2 | 0.60 (0.40–0.80) | 0.86 (0.79–0.94) |
| ACE-inhibitor | 110 | 99.1 | 0.96 (0.90–1.00) | 0.99 (0.97–1.00) |
| A2-receptor blocker | 110 | 93.6 | 0.75 (0.58–0.93) | 0.93 (0.87–0.98) |
| Beta blocker | 110 | 94.5 | 0.87 (0.77–0.97) | 0.93 (0.88–0.99) |
| Calcium channel blocker | 109 | 96.3 | 0.83 (0.66–0.99) | 0.96 (0.92–0.99) |
| Statins | 110 | 96.4 | 0.93 (0.86–1.00) | 0.95 (0.93–1.00) |
aObserved agreement calculated as concordant answers divided by N
Intraclass correlation coefficient for two time variables
| Variable | N | ICC (95 % CI) | Mean diff.b | SDc |
|---|---|---|---|---|
| Stroke onset time (min)a | 42 | 0.93 (0.88–0.96) | 26.38 | 121.60 |
| Hospital admission time (min)a | 89 | 0.98 (0.97–0.99) | 0.45 | 64.50 |
aCalculated as minutes past midnight
bMean difference in minutes calculated as nurse minus Stroke Register
cStandard deviation of the difference